Health economics of obstructive sleep apnea (OSA) airway stimulation

Roughly one in fifteen adults suffers from moderate to severe obstructive sleep apnea (OSA), which can lead to injuries caused by fatigue, stroke and heart attack due to high blood pressure. It is therefore a treatment worthy disease.

In addition to various non-invasive methods of therapy, there is also a new operational approach that is currently certified CE and therefore released for sale in Europe.

Dwh is realizing a parametrization of a Health Technology Assessment respectively cost-effectiveness-evaluation for impartial valuation of this new, US technology for airway stimulation in the Austrian context. The results are immediate element if the refunding discussion.